RA Capital Extends Buying Streak with Another $2.6M in Artiva Shares
ARTV has more than doubled off its 52-week low of $2.22.
Summary
RA Capital, a major institutional investor and board member, purchased $2.58 million of Artiva Biotherapeutics stock in open-market transactions, continuing a pattern of aggressive accumulation.
Key Events · Ownership and Investor Activity · ARTV
-
RA Capital Buys $2.58M More Stock
RA Capital, a director and 10% owner, acquired 264,586 shares at prices between $9.55 and $9.96, totaling $2.58 million, across three days (July 21-23).
-
Stake Increases to 17.2M Shares
Post-transaction, RA Capital holds 17,242,483 shares, representing a significant ownership position built through repeated open-market purchases.
-
Part of $130M Accumulation Trend
This purchase extends a 90-day buying streak by RA Capital, which has deployed over $130 million in Artiva stock, signaling strong conviction in the company's prospects.
-
Follows Positive Clinical Data and Offering
The buying comes after Artiva reported positive AlloNK data in autoimmune diseases and completed a $300 million public offering in May, providing a cash runway for pivotal trials.
Analysis · ARTV · Life Sciences
RA Capital, a director and 10% owner, added $2.58 million to its Artiva Biotherapeutics position over three days, paying between $9.55 and $9.96 per share. This marks the latest in a series of open-market purchases by the healthcare-focused fund, which has now deployed over $130 million in the stock during the past 90 days. The sustained accumulation by a knowledgeable insider with board representation reinforces conviction in the company's autoimmune pipeline, particularly following positive AlloNK data and a $300 million offering in May. The purchase represents 0.525% of the company's market cap, a notable addition to an already large position.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1692 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTV was trading at $10.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $492.2M. The 52-week trading range was $2.22 to $14.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.